By IDSE News Staff
In the first study to directly compare dolutegravir (DTG) with other antiretroviral therapy (ART) listed as “preferred” in the U.S. perinatal HIV guidelines, pregnant individuals who took DTG-based regimens showed a high probability of being virally suppressed at delivery.
Dolutegravir-based ART for HIV-1 is more effective in those patients than some other ART regimens commonly used in the United States and Europe, according to a study led by researchers at Harvard